日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Botensilimab, an Fc-Enhanced Anti-CTLA-4 Antibody, Is Effective against Tumors Poorly Responsive to Conventional Immunotherapy.

Botensilimab 是一种 Fc 增强型抗 CTLA-4 抗体,对传统免疫疗法反应不佳的肿瘤有效

Chand Dhan, Savitsky David A, Krishnan Shanmugarajan, Mednick Gabriel, Delepine Chloe, Garcia-Broncano Pilar, Soh Kah Teong, Wu Wei, Wilkens Margaret K, Udartseva Olga, Vincent Sylvia, Joshi Bishnu, Keith Justin G, Manrique Mariana, Marques Marilyn, Tanne Antoine, Levey Daniel L, Han Haiyong, Ng Serina, Ridpath Jackson, Huber Olivia, Morin Benjamin, Galand Claire, Bourdelais Sean, Gombos Randi B, Ward Rebecca, Qin Yu, Waight Jeremy D, Costa Matthew R, Sebastian-Yague Alvaro, Rudqvist Nils-Petter, Pupecka-Swider Malgorzata, Venkatraman Vignesh, Slee Andrew, Patel Jaymin M, Grossman Joseph E, Wilson Nicholas S, Von Hoff Daniel D, Stebbing Justin, Curiel Tyler J, Buell Jennifer S, O'Day Steven J, Stein Robert B

Fc Receptor-Mediated Activities of Env-Specific Human Monoclonal Antibodies Generated from Volunteers Receiving the DNA Prime-Protein Boost HIV Vaccine DP6-001

从接受 DNA 启动-蛋白加强 HIV 疫苗 DP6-001 的志愿者体内产生的 Env 特异性人单克隆抗体的 Fc 受体介导活性

Costa, Matthew R; Pollara, Justin; Edwards, Regina Whitney; Seaman, Michael S; Gorny, Miroslaw K; Montefiori, David C; Liao, Hua-Xin; Ferrari, Guido; Lu, Shan; Wang, Shixia